For updated information about JADPRO Live 2022, please visit JADPROLive.com

For information about the JADPRO Workshop, please visit JADPROworkshop.com

CURRENT ISSUE Current Issue Cover
VOL 13 NO 8 • Nov/Dec 2022
IN THIS ISSUE

JADPRO Live 2022: Reaching the Peak of Practice

Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO



Adherence to Prophylactic Anticonvulsant Guidelines for Newly Diagnosed Brain Tumor Patients: A Quality Improvement Study

Dan Beverly Fu,(1) DNP, MBA, NP-C, Xiao-Tang Kong,(1) MD, PhD, Tener Goodwin Veenema,(2) PhD, MPH, MS, Daniela A. Bota,(1) MD, PhD, and Binu Koirala,(3) PhD, MGS, RN

 
Section Seperator

TODAY'S NEWS

Lu-177 Vipivotide Tetraxetan Shows Benef...

On December 5, Novartis announced the pivotal phas...

Avoidance of Surgery in Patients With In...

In a phase II trial reported in The Lancet Oncolog...

Short Course of Radiotherapy With Concur...

A 3-week course of radiation therapy including a c...

Study Finds Nearly Half of Black Women W...

When Stephanie L. Walker, RN, was diagnosed with m...

Adjuvant Pembrolizumab May Improve Quali...

Taken together with the primary clinical results, ...

More News From Today More News
Section Seperator

EDITORIALS & COMMENTARY

Advanced Practitioners as Allies and Advocates

Advanced practitioners (APs) are a growing proportion of the health-care team...

Rare Myeloproliferative Neoplasm w/CSF3R

Cases of chronic neutrophilic leukemia (CNL) are extremely rare and easily missed...

Management of Carcinoid Syndrome

Diarrhea is often a presenting symptom in patients with neuroendocrine tumors...

APs: Collaborators in Radiation Oncology

Advanced practitioners, including physician assistants and nurse practitioners, are medical professionals with...

Axicabtagene Ciloleucel: CAR T-Cell Therapy

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy...

More Editorials & Commentary More Tweets
 
Section Seperator

PREVIOUS HIGHLIGHTS

Gemcitabine/Eribulin in Cisplatin-Inelig...

In the final analysis from a phase II California C...

Deintensified Chemoradiotherapy for HPV-...

In a phase II trial reported in the Journal of Cli...

USPSTF Recommendation on Risk Assessment...

As reported in JAMA, the U.S. Preventive Services ...

Incidence of HPV-Associated Head and Nec...

In a study by Mahal et al published in Cancer Epid...

Racial Reporting and Representation in O...

New research published by Loree et al in JAMA Onco...

More Highlights More Highlights
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
 
 
Designed by Harborside
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.